For up to 20 years, the human body may have been conducting a silent, invisible battle against Parkinson's disease, emitting a molecular distress signal that doctors have never detected. New research indicates that this early warning does not become louder as the disease progresses. Instead, it goes away. 

Scientists at Chalmers University of Technology in Sweden, in collaboration with Oslo University Hospital, discovered a collection of biological markers in blood that appear only in the early stages of Parkinson's disease—long before tremors, stiffness, or slower movement appear. As the disease develops, these indicators vanish, shutting a crucial window of chance. 

The findings, published in the journal npj Parkinson's Disease, could change the way the world views early detection of one of the most common neurological conditions, impacting over 10 million people worldwide. With an ageing population, this figure is predicted to more than quadruple by 2050. 

Why Parkinson's is usually diagnosed too late? 

Parkinson's illness progresses slowly. By the time observable motor symptoms occur, 50 to 80 per cent of critical brain cells have already been destroyed or killed; therefore, treatment is primarily concerned with treating symptoms rather than curing the condition. 

"By the time motor symptoms of Parkinson's disease appear, extensive brain damage has often already occurred," said Danish Anwer, a doctorate researcher at Chalmers University and the study's lead author. "This study is an important step towards identifying the disease much earlier and counteracting its progression." 

Until now, doctors have looked for evidence of harm. This study took a different strategy, looking for evidence of the body's defence. 

The Body's Early SOS—And Why It Stays Silent 

The researchers concentrated on two natural protective systems that operate in the body's initial response to sickness. The first is DNA damage repair, the cell's built-in process for correcting genetic damage. The second is the cellular stress response, which assists cells in surviving attacks by halting normal activity and prioritising repair. 

Using machine learning, the team discovered a distinct pattern of gene activity associated with these processes in persons in the very early stages of Parkinson's disease—sometimes up to two decades before symptoms. Importantly, this pattern was absent in both healthy people and patients who already had Parkinson's symptoms. 

"This means we have identified a clear window of opportunity," said Annikka Polster, Assistant Professor at Chalmers University, who conducted the research. "These biological patterns are only active early on and are no longer switched on once the disease has progressed." 

This reversal contradicts established medical wisdom. In most diseases, indicators grow as the condition progresses. In Parkinson's disease, the early warning signs disappear. 

Why a Blood Test Matters? 

Previous research on early Parkinson's disease diagnosis depended on brain scans or spinal fluid analysis, which are costly, intrusive, and unsuited for large-scale screening. This study demonstrates that newly found biomarkers can be assessed using a simple blood test. 

"In our study, we highlighted biomarkers that reflect early disease biology and showed they can be measured in blood," Polster told me. "This opens the door to cost-effective, accessible screening." 

For nations like India, where specialist neurological services are few and the old population is fast expanding, such a test might be revolutionary. 

When Might This Reach Hospitals? 

The researchers predict that blood tests based on these findings will be available in healthcare settings within the next five years. More research is being conducted to better understand the precise biological mechanisms at work and to improve detection methods. 

In the long run, the discovery could help guide treatment. If scientists can study Parkinson's disease while the body is still battling it, current medications, including those designed for other diseases, may be repurposed to delay or halt progression.

Many people ask whether Parkinson’s disease can be detected before symptoms begin. According to this study, the answer may be yes—but only during a short early window when the body is still actively fighting the disease. There is currently no routine blood test for Parkinson’s in clinics, although researchers say scientific progress is moving steadily in that direction. Parkinson’s is often diagnosed late because early signs are subtle and existing tests look for brain damage rather than the body’s early defence signals. If early testing becomes possible, older adults and people with a family history of the disease are likely to benefit the most. Researchers believe that early trials of such blood tests could begin within the next five years. For now, the discovery offers something rare in Parkinson’s research: time—and a chance to act before the warning disappears.